Bristol-Myers Squibb Company

Bristol-Myers Squibb Company(BMY)股票分析

$59.280

+2.733 (+4.61%)收盤時

Loading chart…
最高
59.385
開盤
56.810
成交量加權均價
58.42
成交量
14.05M
市值
84.14B
最低
56.580
成交金額
820.53M
企業價值/稅息折舊攤銷前利潤(TTM)
7.55

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).

AI 分析 of Bristol-Myers Squibb Company (BMY)

買進

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

分析師評級(22)

-5.77% 下跌空間
持有
9 買進
11 持有
2 賣出
目前: 59.28
最低
37.00
平均
55.86
最高
68.00

Jefferies

2026-10-12

目標價

$76

買進

William Blair

2026-10-12

目標價

—

Market Perform

BofA

2026-10-09

目標價

$66

買進

Cantor Fitzgerald

2026-10-08

目標價

$53

中性

Morgan Stanley

2026-10-07

目標價

$41

減持

估值指標

Bristol-Myers Squibb Company(BMY)目前預期本益比為 9.36,5 年平均預期本益比為 11.38。

預期本益比

合理
5 年均值 P/E
11.38
目前P/E
9.36
高估
24.94
低估
-2.19

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
10.20
目前EV/EBITDA
7.55
高估
14.39
低估
6.01

預期股價營收比

合理
5 年均值 P/S
2.67
目前P/S
2.38
高估
3.19
低估
2.16

Alphio AI 對 BMY 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BMY

$44.66

情境價格

基

基準

基準 · 50%BMY

$40.66

情境價格

悲

悲觀

悲觀 · 25%BMY

$35.77

情境價格

持有 BMY 的大戶

T

Turtle Creek Management, LLC

+ 持有BMY

+21.39%

3個月報酬率

C

Cbus Industry Superannuation Fund

+ 持有BMY

+9.20%

3個月報酬率

D

DWS Investment Management Americas, Inc.

+ 持有BMY

+8.52%

3個月報酬率

N

Nan Shan Life Insurance Co., Ltd.

+ 持有BMY

+8.14%

3個月報酬率

M

Martingale Asset Management, L.P.

+ 持有BMY

+7.91%

3個月報酬率

O

Osmosis Investment Management UK Limited

+ 持有BMY

+7.62%

3個月報酬率

事件時間軸

2026-10-12 (ET)

14:00:00

RBC Analyst Calls Bristol Myers Drug Results Positive

09:00:00

S&P 500 Futures Mixed as Oil Prices Rise

07:00:00

Bristol Myers Squibb Announces Positive ACTION-1 Trial Results

07:00:00

Bristol Myers Squibb Announces Phase 3 Trial Results for Admilparant

2026-10-08 (ET)

07:30:00

Bristol Myers Announces Positive Phase 3 Results for Zenbexus

資訊

BMY 常見問題 —— 由 Alphio AI 解答

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bristol-Myers Squibb is a good buy right now due to its current price of $59.12, which is below the analyst price target of $66 from BofA. Additionally, the company has a strong gross margin of 68.03% reported in Q2 2026, indicating solid profitability. However, the main risk is the declining revenue trend, with a slight decrease of 0.2% year-over-year reported for FY 2025.

22 analysts cover BMY: 9 rate it Buy, 11 Hold and 2 Sell. The average price target is 55.86.

molten_vortex2026/9/26

Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT

展開
RektEddy2026/9/15

$PGR $SYK $BMY Many people enter the crypto space chasing quick profits, but real, consistent success is built on knowledge, discipline, and the right guidance. That’s where having a reliable mentor makes all the difference. Craig has played a key role in helping me understand the markets with more clarity and confidence. His approach to trading goes beyond signals, it’s about building structure, managing risk, and staying focused on long-term growth. With his guidance and his YouTube videos, I’ve been able to make smarter decisions, avoid emotional trading, and stay consistent even in volatile conditions. The shift in mindset alone has been a game changer.

展開
註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易